Key result
A stress hyperglycemia ratio ≥ 0.86 was associated with a significantly increased risk of all-cause mortality (HR 2.065) in patients with chronic kidney disease.
Why the study?
The stress hyperglycemia ratio characterizes acute glycemic rise and links to unfavorable cardiovascular outcomes, but its association with mortality in CKD was unknown.
Does the stress hyperglycemia ratio predict all-cause and cardiovascular mortality in adults with chronic kidney disease?
Cohort (n=3,284)
Yes
Does the stress hyperglycemia ratio predict all-cause and cardiovascular mortality in adults with chronic kidney disease?
Hazard Ratio: 2.065 (95% CI 1.328–3.209)
The stress hyperglycemia ratio demonstrates a non-linear association with all-cause and cardiovascular mortality in patients with chronic kidney disease, highlighting its potential as a prognostic marker for risk stratification.
May support SHR for mortality risk stratification in CKD; leaves open validation beyond observational data.
BACKGROUND: The stress hyperglycemia ratio (SHR) has recently been suggested to characterize acute glycemic rise better than the admission blood glucose and to be associated with unfavorable outcomes in patients with various cardiovascular diseases. This study aimed to explore the associations between SHR and all-cause or cardiovascular disease (CVD) mortality in patients with chronic kidney disease (CKD). METHODS: Adults with CKD participating in the 1999-2018 US National Health and Nutrition Examination Survey with complete SHR and follow-up data were included. SHR was calculated from fasting blood glucose and glycated hemoglobin levels. Associations between SHR and mortality were investigated by weighted multivariable Cox regression analysis. RESULTS: Among the 3284 participants (mean age 61 years, men prevalence 44.09%) included, 1324 (487 CVD-related) deaths occurred during a median follow-up of 87 months. The restricted cubic spline curve adjusted for all covariates showed a U-shaped and J-shaped association between SHR and all-cause or CVD mortality, respectively, with discernible inflection points at 0.86 and 0.88, respectively. The hazard ratio (95% confidence interval) was 0.117 (0.034-0.404) for SHR < 0.86 and 2.065 (1.328-3.209) for SHR ≥ 0.86 for all-cause mortality, and 0.063 (0.008-0.531) for SHR < 0.88 and 1.551 (0.770-3.124) for SHR ≥ 0.88 for CVD mortality. CONCLUSION: We identified U-shaped and J-shaped association between SHR and all-cause or CVD mortality, respectively, in patients with CKD. This result highlights that SHR may be potentially informative for the risk stratification of CKD patients. Given the potential limitations of residual confounding, prospective studies are needed to confirm our findings.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) conducted a cohort in Chronic kidney disease (n=3,284). Stress hyperglycemia ratio (SHR) vs. SHR < 0.86 was evaluated on All-cause mortality (for SHR ≥ 0.86) (HR 2.065, 95% CI 1.328-3.209). A stress hyperglycemia ratio ≥ 0.86 was associated with a significantly increased risk of all-cause mortality (HR 2.065) in patients with chronic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: